Angelman Syndrome Foundation opener
  • Walk
  • Contact Registry
  • News
  • Blog
DOnate
  • What is Angelman Syndrome
    • Symptoms and Causes
    • Testing and Diagnosis
    • Genetics of AS
    • Photo Gallery
  • For Parents
    • Newly Diagnosed
    • Accomplishments of Individuals
    • Participate in Research Studies
    • Angelman Therapeutics
  • Research
    • ASF Funded Research
    • Call for Proposals
    • Current Research Studies
    • Research Funding Philosophy
  • Make an Impact
    • ASF Cure Club
    • Ways To Donate
    • Fundraising for ASF
    • ASF Committees
    • Shop & Support ASF
    • Volunteer Opportunities
  • AS Clinics
    • AS Clinic Patient Survey
  • Resources
    • Search by Topic
    • Adult Resources
    • ASF Family Resource Team
    • ASF Family Fund
    • ASF Family Champions
    • Angelman Syndrome A to Z
    • Communication Training Series
    • Behaviors Training Series
    • Educational Webinars
    • IEP Bank
    • International AS Resources
    • Federal Resources
    • Seizures
    • State Resources
  • Events
    • ASF Walk
      • ASF Walk Sponsors
    • Conferences and Symposia
    • Bank of America Chicago Marathon
  • About
    • Contact ASF
    • Contact Registry
    • History
    • Board of Directors
    • Communication Advisory Committee
    • Scientific Advisory Committee
    • Receive Our Emails
    • Privacy
    • Financial Transparency

articles and announcements

Categories: Antisense oligonucleotides

December 21, 2019

The role of antisense RNA Ube3a-ATS in Ube3a imprinting and Angelman syndrome

$100,000 Angelman syndrome is caused by deficiency of UBE3A. Unlike ordinary autosomal genes, it is subject to genomic imprinting with expression only from maternal chromosome. It is unknown how such imprinted status is established, since no differential DNA methylation was […]

Read more
Dr. Arthur Beaudet
December 21, 2019

Ube3a-ATS Targeted Antisense Oligonucleotides As Therapies for Angelman Syndrome

$200,000 (2 years) Oligonucleotides are short, single-stranded DNA or RNA molecules. Previous studies have demonstrated that the antisense RNA of Ube3a (Ube3a-ATS) silences the paternal Ube3a gene. The investigators propose using antisense oligonucleotides (ASOs) to specifically target Ube3a-ATS, which is […]

Read more
December 14, 2019

Testing the efficacy of antisense oligonucleotides (ASOs) against UBE3A-ATS in human neurons

$200,000 (2 years) This research study builds upon previous ASF-funded research conducted by Dr. Art Beaudet at Baylor College of Medicine and will determine whether a drug that increases UBE3A expression can restore normal function to human AS brain cells. […]

Read more

Recent Posts

  • Joint Initiative between ASA and ASF
  • Groundbreaking ASF Funded Research on Gene Therapy in AS Published in Nature
  • Ovid Therapeutics Collaborates with UCONN Health and Stormy Chamberlain, PhD to Develop Gene Therapy for AS
  • CASS and ASF Announce Collaboration to Increase Support for Families 
  • Ben Philpot, PhD Partners with Deerfield and Pinnacle Hill

Browse

  • What is Angelman Syndrome
  • For Parents
  • ASF Funded Research
  • Make an Impact
  • Angelman Syndrome Clinic Network
  • Events
  • About
  • Resources & Education
  • Contact Registry
  • News
Address Angelman Syndrome Foundation
3015 E. New York Street
Suite A2 #285
Aurora, IL 60504
Phone800.432.6435 Emailinfo@angelman.org

Connect

  • facebook
  • twitter
  • linkedin
  • instagram
  • pinterest
  • rss
  • youtube

The Mission

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.

Copyright © 2021 Angelman Syndrome Foundation. ALL Rights Reserved. | Site design: BRAND INSPIRATION, LLC